Chronic Early-Stage Ocular Cicatricial Pemphigoid.


Journal

Ophthalmic plastic and reconstructive surgery
ISSN: 1537-2677
Titre abrégé: Ophthalmic Plast Reconstr Surg
Pays: United States
ID NLM: 8508431

Informations de publication

Date de publication:
Historique:
pubmed: 23 7 2021
medline: 16 11 2021
entrez: 22 7 2021
Statut: ppublish

Résumé

Ocular cicatricial pemphigoid (OCP) represents an insidious, autoimmune-mediated disease of the conjunctiva, initially presenting as chronic conjunctivitis and progressing to fibrosis, cicatrization, and eventually blindness secondary to corneal keratinization. This series reports 3 cases presenting with chronic conjunctivitis lasting an average of 10 years without cicatrix formation, ultimately diagnosed as OCP based on direct immunofluorescence of conjunctival biopsy samples. This chronic conjunctivitis without fibrosis suggests the possibility of an OCP subtype with a prolonged early stage or prodrome prior to cicatrization, which may benefit from early diagnosis and treatment to prevent complications of this disease.

Identifiants

pubmed: 34293790
doi: 10.1097/IOP.0000000000002021
pii: 00002341-202111000-00028
doi:

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e209-e213

Informations de copyright

Copyright © 2021 The American Society of Ophthalmic Plastic and Reconstructive Surgery, Inc.

Déclaration de conflit d'intérêts

The author has no conflicts of interest.

Références

Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol. 2002;138:370–379.
Tauber J, Melamed S, Foster CS. Glaucoma in patients with ocular cicatricial pemphigoid. Ophthalmology. 1989;96:33–37.
Georgoudis P, Sabatino F, Szentmary N, et al. Ocular mucous membrane pemphigoid: current state of pathophysiology, diagnostics and treatment. Ophthalmol Ther. 2019;8:5–17.
Fremont F, Pelissier-Suarez C, Fournié P, et al. Clinical characteristics and outcomes of ocular cicatricial pemphigoid: a cohort study and literature review. Cornea. 2019;38:1406–1411.
Ong HS, Setterfield JF, Minassian DC, et al.; Mucous Membrane Pemphigoid Study Group 2009–2014. Mucous membrane pemphigoid with ocular involvement: the clinical phenotype and its relationship to direct immunofluorescence findings. Ophthalmology. 2018;125:496–504.
Power WJ, Neves RA, Rodriguez A, et al. Increasing the diagnostic yield of conjunctival biopsy in patients with suspected ocular cicatricial pemphigoid. Ophthalmology. 1995;102:1158–1163.
Franklin RM, Fitzmorris CT. Antibodies against conjunctival basement membrane zone. Occurrence in cicatricial pemphigoid. Arch Ophthalmol. 1983;101:1611–1163.
Foster CS, Wilson LA, Ekins MB. Immunosuppressive therapy for progressive ocular cicatricial pemphigoid. Ophthalmology. 1982;89:340–353.
Foster CS. Cicatricial pemphigoid. Trans Am Ophthalmol Soc. 1986;84:527–663.
Thorne JE, Anhalt GJ, Jabs DA. Mucous membrane pemphigoid and pseudopemphigoid. Ophthalmology. 2004;111:45–52.
Anesi SD, Eggenschwiler L, Ferrara M, et al. Reliability of conjunctival biopsy for diagnosis of ocular mucous membrane pemphigoid: redetermination of the standard for diagnosis and outcomes of previously biopsy-negative patients [published online ahead of print March 4, 2020]. Ocul Immunol Inflamm. doi: 10.1080/09273948.2020.1716988.
doi: 10.1080/09273948.2020.1716988
Leonard JN, Hobday CM, Haffenden GP, et al. Immunofluorescent studies in ocular cicatricial pemphigoid. Br J Dermatol. 1988;118:209–217.
Letko E, Miserocchi E, Daoud YJ, et al. A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies. Clin Immunol. 2004;111:303–310.
Wang K, Seitzman G, Gonzales JA. Ocular cicatricial pemphigoid. Curr Opin Ophthalmol. 2018;29:543–551.
Taurone S, Spoletini M, Ralli M, et al. Ocular mucous membrane pemphigoid: a review. Immunol Res. 2019;67:280–289.
Faulds D, Goa KL, Benfield P. Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs. 1993;45:953–1040.

Auteurs

Sonya Besagar (S)

Columbia University, Vagelos College of Physicians and Surgeons, New York, New York, U.S.A.

Ashley O London (AO)

Columbia University, Vagelos College of Physicians and Surgeons, New York, New York, U.S.A.

Meghan P Jairam (MP)

Columbia University, Vagelos College of Physicians and Surgeons, New York, New York, U.S.A.

Danielle Trief (D)

Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Irving Medical Center, New York, New York, U.S.A.

Lora R Dagi Glass (LR)

Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Irving Medical Center, New York, New York, U.S.A.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH